Boston, Massachusetts 2022-05-27 11:49:24 –
MeIn response to criticism, ViiV Healthcare will license a long-acting, injectable HIV prevention shot to the drug patent pool so that generic companies can create cheaper versions and distribute them to low- and middle-income countries. I agreed. However, due to drug schedules and current pricing, this move has faced various reactions.
This move will take place two months after the announcement, primarily by companies managed by GSK. Will not pursue All license agreements and instead plan to remain the “only supplier” of Apretude Shot on a global basis, at least for the first launch period.Injectables have recently been approved in the United States
ViiV will let generics copy its HIV prevention shot, but it’s not clear when Source link ViiV will let generics copy its HIV prevention shot, but it’s not clear when